Cost of sales, excluding amortization and impairment of acquired intangible assets
Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $358.40M | $468.20M | $399.90M | $462.20M | $415.00M | $384.00M | $326.00M | $478.70M |
| Royalty and other revenue | $187.60M | $170.50M | $183.60M | $167.10M | $190.00M | $290.40M | $169.50M | $182.30M |
| Clinical Inventory | $46.00M | $2.50M | — | $5.98M | $5.98M | $5.98M | $5.98M | $56.80M |
| SPINRAZA | $54.03M | $54.03M | $54.03M | $53.08M | $53.08M | $53.08M | $53.08M | — |
| Total | $546.00M | $638.70M | $583.50M | $629.30M | $605.00M | $674.40M | $495.50M | $661.00M |
SPINRAZA is derived from annual filings.
Segments
Clinical InventoryView metric
Product revenue, netView metric
Royalty and other revenueView metric
SPINRAZAView metric